Coating of fast absorption or dissolution

Abstract

A coating of fast absorption or fast dissolution on an implantable device and methods of making and using of the coating are provided.

1 . A coating on an implantable device, the coating comprising
 a soluble or fast absorption polymer or material, and   optionally between about 1% and about 20% of a low molecular weight polymer,   wherein the coating has a thickness from about 1 μm to about 100 μm and about 50 wt % or more of the coating can absorb or dissolve within 24 hours after implantation.   
     
     
         2 . The coating of  claim 1 , wherein the low molecular weight polymer has a weight-average molecular weight (M w ) below about 45,000 Daltons. 
     
     
         3 . The coating of  claim 1 , wherein the low molecular weight polymer has a weight-average molecular weight (M w ) below about 45,000 Daltons and comprises acidic or basic pendant groups. 
     
     
         4 . The coating of  claim 1 , wherein the soluble or fast absorption polymer or material comprises an ionic or non-ionic polymer. 
     
     
         5 . The coating of  claim 1 , wherein the soluble or fast absorption polymer or material comprises poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), hyaluronic acid, hydroxyl cellulose, CMC (carboxymethyl cellulose), hydroxy propyl methyl cellulose (HPMC), hydroxy propyl methacrylamide (HPMA), poly(butylene terephthalate-co-poly(ethylene glycol) (PBT-PEG), poly(butylene terephthalate-co-carboxy methyl cellulose) (PBT-co-CMC), polysaccharide, chitosan, collagen, PLA, PLGA, PEA, polyacylate, polymethacrylate or a combination thereof. 
     
     
         6 . The coating of  claim 1 , wherein the soluble or fast absorption polymer or material has a M w  of 10,000 Daltons to about 150,000 Daltons. 
     
     
         7 . The coating of  claim 1 , wherein the low molecular weight polymer has a weight-average molecular weight (M w ) above 20,000 Daltons and where the polymer would be removed from the stent by solubilization and then while in the tissue (blood, kidneys) would degrade to low molecular weights to allow for kidney clearance. 
     
     
         8 .- 17 . (canceled) 
     
     
         18 . The coating of  claim 1 , wherein the implantable device is stent. 
     
     
         19 . The coating of  claim 1 , further comprising a bioactive agent. 
     
     
         20 . The coating of  claim 1 , further comprising an agent selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin(everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prodrugs thereof, or a combination thereof. 
     
     
         21 . A method of treating a human being by implanting in the human being an implantable device comprising the coating of  claim 20 ,
 wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.